Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Dexamethasone for Neuroinflammation Research: Applied Wor...
2025-10-03
Dexamethasone (DHAP) is redefining experimental research in neuroinflammation, stem cell biology, and immunology with its unique inhibition of NF-κB signaling and tailored delivery options. This guide details how to harness its potent glucocorticoid anti-inflammatory effects, optimize protocols, and troubleshoot common challenges to accelerate discovery.
-
SCH772984 HCl: Selective ERK1/2 Inhibitor for MAPK Pathwa...
2025-10-02
SCH772984 HCl redefines precision in targeting MAPK signaling, offering robust inhibition of ERK1/2 for cancer and stem cell research. Its nanomolar potency, proven antiproliferative activity, and capacity to overcome resistance make it indispensable for dissecting complex oncogenic pathways and telomerase regulation.
-
Oxaliplatin Resistance: Mechanisms, Overcoming Strategies...
2025-10-01
Explore the unique cellular and molecular mechanisms driving Oxaliplatin resistance in cancer chemotherapy. This in-depth review highlights DNA adduct formation, platinum-DNA crosslinking, and novel combination strategies for metastatic colorectal cancer therapy.
-
Redefining mRNA Tools for Translational Research: Strateg...
2025-09-30
This thought-leadership article explores how cutting-edge mRNA engineering—exemplified by EZ Cap™ EGFP mRNA (5-moUTP)—is transforming translational gene expression studies. By integrating mechanistic rationale, experimental validation, and strategic guidance, we elucidate how Cap 1 capping, 5-moUTP modification, and poly(A) tailing together suppress innate immunity, boost translation, and enable high-fidelity in vivo imaging. We contextualize these innovations within the competitive and clinical landscape, drawing on recent research in mRNA delivery and immunotherapy, and offer a forward-looking perspective for translational investigators.
-
EZ Cap™ Human PTEN mRNA (ψUTP): Redefining Functional mRN...
2025-09-29
Explore how EZ Cap™ Human PTEN mRNA (ψUTP) revolutionizes mRNA-based gene expression studies by integrating Cap1 and pseudouridine modifications for enhanced stability and immune evasion. Discover unique mechanistic insights and translational strategies that set this approach apart in advanced cancer research.
-
MG-132: Advanced Insights into Ubiquitin-Proteasome Syste...
2025-09-28
Explore the multifaceted role of MG-132, a potent proteasome inhibitor peptide aldehyde, in apoptosis research and cancer biology. This article uniquely dissects the mechanistic interplay between ubiquitin-proteasome system inhibition, ROS signaling, and autophagy, offering new perspectives beyond current literature.
-
5-Methyl-CTP: Transforming mRNA Stability for Novel Vacci...
2025-09-27
Discover how 5-Methyl-CTP, a leading modified nucleotide for in vitro transcription, empowers next-generation mRNA synthesis with enhanced stability and translation efficiency. This article uniquely explores its integration into emerging vaccine delivery systems and offers a deeper mechanistic perspective on mRNA degradation prevention.
-
X-press Tag Peptide: Next-Gen Tag for Post-Translational ...
2025-09-26
Explore how the X-press Tag Peptide revolutionizes protein purification and detection, with unique insights into its role in post-translational modification research. Discover advanced technical strategies and scientific context for this N-terminal leader peptide.
-
MLN4924: Redefining Neddylation Pathway Targeting in Soli...
2025-09-25
Explore how MLN4924, a selective NEDD8-activating enzyme inhibitor, enables next-generation cancer biology research through precise neddylation pathway inhibition. This article uniquely examines MLN4924’s mechanistic impact on cullin and non-cullin substrates in solid tumor models, offering fresh insights for anti-cancer therapeutic development.
-
TCEP Hydrochloride: Enabling Next-Gen Capture-and-Release...
2025-09-24
Explore how TCEP hydrochloride, a water-soluble reducing agent, empowers advanced capture-and-release strategies and sensitivity enhancement in lateral flow and protein analysis assays. Gain a mechanistic, application-focused perspective distinct from standard protocols.
-
Angiotensin II and Senescence-Driven AAA: Novel Mechanist...
2025-09-23
Explore the distinct interplay between Angiotensin II signaling and cellular senescence in abdominal aortic aneurysm (AAA) pathogenesis. This article highlights Angiotensin II as a potent vasopressor and GPCR agonist, offering new perspectives for cardiovascular remodeling investigation and hypertension mechanism study.
-
AR is an enzyme involved in conversion of
2025-03-03

AR is an enzyme involved in conversion of glucose into sorbitol using NADPH as a cofactor [46]. This AR polyol pathway generates sorbitol accumulation and NADPH depletion. NADPH participates in detoxification via glutathione (GSH) reductase pathway [47]. Therefore, reduction of NADPH attenuates remo
-
The functional observations from the
2025-03-03

The functional observations from the present study are based on neoplastic Fluorescent labeling antibody (HSY), and comparative expressions between normal salivary and pleomorphic adenoma tissues. However, there is a paucity of information on AhR expression and function in normal salivary gland, no
-
Unexpectedly under pathological pain conditions inhibition o
2025-03-03

Unexpectedly, under pathological pain conditions, inhibition of spinal glutamate transporter activity can produce antinociceptive effects. For example, intrathecal injection of the transportable inhibitor trans-pyrrolidine-2,4-dicarboxylic fructose and fructose (t-PDC) or antisense oligonucleotides
-
Because activation of HT A
2025-03-03

Because activation of 5-HT2A receptor is capable of facilitating dopamine cell activity and dopamine release (Bortolozzi et al., 2003), and this action of dopamine is known to mediate rat maternal behavior, especially maternal motivation (Afonso et al., 2007, Febo et al., 2010, Li and Fleming, 2003,
16730 records 21/1116 page Previous Next First page 上5页 2122232425 下5页 Last page